Genaissance Sees New Life For Vilazodone With Pharmacogenomics
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm licenses antidepressant from Merck KGaA after lack of efficacy in Phase II caused GlaxoSmithKline to drop project. Phase II trials to identify genetic markers of response will start in first half of 2005, with goal of developing drug/diagnostic package.
You may also be interested in...
Clinical Data CEO Drew Fromkin: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
Fromkin and Chief Medical Officer Reed talk about their targeted antidepressant vilazodone and the firm’s plans for developing other drugs with companion diagnostics.
Clinical Data CEO Drew Fromkin: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
Fromkin and Chief Medical Officer Reed talk about their targeted antidepressant vilazodone and the firm’s plans for developing other drugs with companion diagnostics.
Office Of Combination Products Should Coordinate, Not Review Rx/Dx Products, Roche Says
"Partner" products should be reviewed and approved by their respective division, Roche Regulatory Affairs Director Lois Hinman, PhD, says. FDA's draft guidance on co-development of drug/diagnostic products is expected by year-end. The agency is finalizing its pharmacogenomics data submission guidance.